Role of UHRF1 in malignancy and its function as a therapeutic target for molecular docking towards the SRA domain

[Display omitted] •UHRF1 is upregulated in several cancers.•UHRF1 levels are associated with stage, size and grade of the tumor.•UHRF1 can be used as a druggable target.•Docking of Propranolol, Nocodazole, Thymoquinone, Emodin, Napthazarin to SRA domain. The figure describes the location of UHRF1 (U...

Full description

Saved in:
Bibliographic Details
Published in:The international journal of biochemistry & cell biology 2019-09, Vol.114, p.105558-105558, Article 105558
Main Authors: Polepalli, Sravani, George, Sophia M, Valli Sri Vidya, R, Rodrigues, Gabriel Sunil, Ramachandra, L., Chandrashekar, Raghu, M, Deepak Nayak, Rao, Praveen P.N., Pestell, Richard G., Rao, Mahadev
Format: Article
Language:English
Subjects:
Animals
Cancer
CCAAT-Enhancer-Binding Proteins - chemistry
CCAAT-Enhancer-Binding Proteins - genetics
CCAAT-Enhancer-Binding Proteins - metabolism
Humans
Molecular Docking Simulation
Neoplasm Proteins - chemistry
Neoplasm Proteins - genetics
Neoplasm Proteins - metabolism
Neoplasms - genetics
Neoplasms - metabolism
Neoplasms - pathology
Neoplasms - therapy
Protein Domains
SRA domain
Ubiquitin-Protein Ligases - chemistry
Ubiquitin-Protein Ligases - genetics
Ubiquitin-Protein Ligases - metabolism
UHRF1
Universal oncogene
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •UHRF1 is upregulated in several cancers.•UHRF1 levels are associated with stage, size and grade of the tumor.•UHRF1 can be used as a druggable target.•Docking of Propranolol, Nocodazole, Thymoquinone, Emodin, Napthazarin to SRA domain. The figure describes the location of UHRF1 (Ubiquitin-like with containing PHD and RING Finger domains 1) gene, mRNA and protein synthesis in the tumor cell and its structural domains with a focus on the docking of Naphthazarin on the SRA domain of UHRF1, resulting in reduction of tumor size.
ISSN:1357-2725
1878-5875
DOI:10.1016/j.biocel.2019.06.006